Extracting the probes located in this blood GLIPR1L2 DMR from the MTG EWAS for comparison showed, in AD cases, lower UC levels (9/10 probes with negative log2 fold change [logFC]), mixed changes for 5mC (6/10 probes with positive logFC), and lower 5hmC levels for the probes that passed the detection threshold (2/2 probes with negative logFC). This evidence concerns the gene GLIPR1L2 and Alzheimer disease.